Transendothelial migration (TEM) of in vitro generated dendritic cell vaccine in cancer immunotherapy

Ashraf, Muhammad; Jeong, Yideul; Roh, Seung-Eon; Bae, Yong-Soo

doi:10.1007/s12272-019-01145-w

Cited by 3 publications

(1 citation statement)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is crucial to understand how this virus elicits immune responses and whereby evades those immune responses to survive and replicate in the body, and this information is vital for the development of a safe and efficient vaccine and/or immunotherapy against the virus. Like MERS-CoV and SARS-CoV, two of the phylogenetically similar viruses, SARS-CoV-2 causes suppression of the innate immune system including the dendritic cells (DCs) and diminishes the antiviral interferons (type I and III IFNs) [ 8 , 9 , 10 , 11 ]. Meanwhile, it has also been demonstrated that SARS-CoV-2 elicits an acute hyper-inflammatory response, like cytokine storm, leading to worse prognosis and increased fatality rate (FR) in infected patients [ 12 ].…”

Section: Introductionmentioning

confidence: 99%

COVID-19 Vaccines (Revisited) and Oral-Mucosal Vector System as a Potential Vaccine Platform

et al. 2021

Self Cite

View full text Add to dashboard Cite

There are several emerging strategies for the vaccination of COVID-19 (SARS-CoV-2) however, only a few have yet shown promising effects. Thus, choosing the right pathway and the best prophylactic options in preventing COVID-19 is still challenging at best. Approximately, more than two-hundred vaccines are being tested in different countries, and more than fifty clinical trials are currently undergoing. In this review, we have summarized the immune-based strategies for the development of COVID-19 vaccines and the different vaccine candidate platforms that are in clinical stages of evaluation, and up to the recently licensed mRNA-based COVID-19 vaccines of Pfizer-BioNtech and Moderna’s. Lastly, we have briefly included the potentials of using the ‘RPS-CTP vector system’ for the development of a safe and effective oral mucosal COVID-19 vaccine as another vaccine platform.

show abstract

Section: Introductionmentioning

confidence: 99%

COVID-19 Vaccines (Revisited) and Oral-Mucosal Vector System as a Potential Vaccine Platform

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

Engineered nanoparticles to enhance natural killer cell activity towards onco-immunotherapy: a review

2020

View full text Add to dashboard Cite

Therapeutic Potential of microRNA Against Th2-associated Immune Disorders

Kumar

Ashraf

Kumar

et al. 2021

CTMC

View full text Add to dashboard Cite

: MicroRNAs (miRNAs) are short ~18-22 nucleotide, single-stranded, non-coding RNA molecules playing a crucial role in regulating diverse biological processes, and are frequently dysregulated during disease pathogenesis. Thus, targeting miRNA could be a potential candidate for therapeutic invention. This systemic review aims to summarize our current understanding regarding the role of miRNAs associated with Th2-mediated immune disorders and strategies for therapeutic drug development and current clinical trials.

show abstract

Transendothelial migration (TEM) of in vitro generated dendritic cell vaccine in cancer immunotherapy

Cited by 3 publications

References 60 publications

COVID-19 Vaccines (Revisited) and Oral-Mucosal Vector System as a Potential Vaccine Platform

COVID-19 Vaccines (Revisited) and Oral-Mucosal Vector System as a Potential Vaccine Platform

Engineered nanoparticles to enhance natural killer cell activity towards onco-immunotherapy: a review

Therapeutic Potential of microRNA Against Th2-associated Immune Disorders

Contact Info

Product

Resources

About